Business News • PR NewsWire • Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant

Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant

Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant

CHADDS FORD, Pa., Jan. 7, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its new formulation of OPANA® ER designed to be crush resi

View More : http://www.prnewswire.com/news-releases/endo-pharmaceuticals-provides-regulatory-update-on-new-formulation-of-opana-er-d...

Releted News by prnewswire